RepliCel Life Sciences Inc. (OTCMKTS:REPCF) Stock gains Momentum: Jumps 8% In a Week

RepliCel Life Sciences Inc. (OTCMKTS:REPCF) is up 8% in a week. The company announced the submission of a new patent application that covers novel aspects of the DermaPrecise product portfolio and the allowance and granting of three patent applications in major.

Market Stats

On Monday, REPCF stock ended flat at $0.2034 with 5.2k shares, compared to its average volume of 8.4k shares. The stock has moved within a range of $0.2034 – 0.2034 after opening trading at $0.2034.

RepliCel Announces Material Patent Milestones

The DermaPrecise Injector is an injection technology that provides unprecedented control levels over any shot into the skin and subcutaneous layers when depth, dosage, and/or delivery precision are essential. This latest provisional patent filing, submitted on November 11, 2021, covers novel commercial embodiments of several technologies relating to the company’s dermal injector product line that was not included in previous patent filings.

The company’s CEO and President R. Lee Buckler said that as the company continues to advance the DermaPrecise injector, consumables, and control units, they will continue submitting patents to protect all the product’s aspects. Notably, the testing done on the Dermaprecise injection system is creating new ideas, specifications, and innovations, resulting in more patent submission covering new tech and applications. So, REPCF is worth watching.

Key Quote

“As we continue to innovate the DermaPrecise™ injector, control unit and consumables, we will continue to file patents protecting all aspects of this product portfolio,” stated RepliCel President and CEO, R. Lee Buckler. “The testing being conducted on the DermaPrecise™ injection system is generating new ideas, innovations, and specifications which will lead to more patent filings covering new technologies and applications as we march toward commercialization of the DermaPrecise™ product line.”

Traders Corner

REPCF stock is trading below the 20-Day and 50-Day Moving averages of $0.21 and $0.22 respectively. Moreover, the stock is trading below the 200-Day moving average of $0.27.